Zacks Investment Research lowered shares of Glaukos Corporation (NYSE:GKOS) from a buy rating to a hold rating in a research report report published on Monday.

According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “

Several other research firms have also commented on GKOS. BMO Capital Markets reaffirmed a buy rating and set a $54.00 price target on shares of Glaukos Corporation in a research report on Tuesday, April 11th. Piper Jaffray Companies reaffirmed a buy rating and set a $56.00 price target on shares of Glaukos Corporation in a research report on Thursday, August 3rd. Roth Capital reduced their price target on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating for the company in a research report on Thursday, August 3rd. BidaskClub raised shares of Glaukos Corporation from a hold rating to a buy rating in a research report on Saturday, June 24th. Finally, TheStreet lowered shares of Glaukos Corporation from a c rating to a d+ rating in a research report on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $52.33.

Shares of Glaukos Corporation (NYSE GKOS) traded down 0.05% during mid-day trading on Monday, hitting $37.40. 8,036 shares of the stock traded hands. Glaukos Corporation has a 1-year low of $28.26 and a 1-year high of $52.49. The company’s 50-day moving average price is $41.36 and its 200 day moving average price is $43.37. The company’s market capitalization is $1.29 billion.

COPYRIGHT VIOLATION WARNING: “Glaukos Corporation (NYSE:GKOS) Lowered to “Hold” at Zacks Investment Research” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/08/glaukos-corporation-nysegkos-lowered-to-hold-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System increased its position in shares of Glaukos Corporation by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 140 shares during the period. State Street Corp increased its position in shares of Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock worth $9,653,000 after buying an additional 18,183 shares during the period. AQR Capital Management LLC bought a new position in shares of Glaukos Corporation during the fourth quarter worth about $513,000. Teachers Advisors LLC increased its position in shares of Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after buying an additional 1,506 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in shares of Glaukos Corporation during the fourth quarter worth about $416,000. Institutional investors own 89.63% of the company’s stock.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.